Compound hub · CJC-1295
What is CJC-1295 with DAC? Meaning, forms and evidence status
CJC-1295 with DAC is a lab-made, 30-amino-acid analogue of growth hormone-releasing hormone (GHRH). It carries a chemical hook called the drug affinity complex (DAC). In rats, the hook bonded it to albumin, a blood protein. That is an animal finding. It does not show the same result in humans (Jetté et al., 2005). It is a peptide. It is not a steroid and not growth hormone itself. In two placebo-controlled trials of healthy adults aged 21 to 61, its estimated half-life was 5.8 to 8.1 days. The abstract gives no head count (Teichman et al., 2006). A 2026 narrative review states it is not an approved medicine (Dominikowski et al., 2026).
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
Look up CJC-1295 and the same few terms keep appearing: DAC, no DAC, steroid, growth hormone. Each term names something different. Your body already makes real growth hormone. It also makes the cue that triggers it. CJC-1295 is neither of those. It is a lab imitation of the cue.
This page is part of the CJC-1295 hub. It sorts out the names first. Then it answers common questions about testosterone, insulin, strength and downsides, using what studies and regulators recorded. For the hormone results, see what studies found CJC-1295 does.
Key facts
| Compound | CJC-1295, a lab-made analogue of growth hormone-releasing hormone (GHRH). |
|---|---|
| With DAC | 30 amino acids: hGRF(1-29) with four substitutions plus an added lysine carrying a maleimide hook (design paper in rats, Jetté et al., 2005). |
| Without DAC | 29-amino-acid backbone without the hook. No peer-reviewed human studies, according to a 2026 narrative review (Dominikowski et al., 2026). |
| Human half-life, with DAC | Estimated 5.8 to 8.1 days in two trials of healthy adults aged 21 to 61. No head count in the abstract. Applies to those volunteers only (Teichman et al., 2006). |
| Drug class | Peptide hormone releasing factor, not a steroid (WADA Prohibited List 2026, S2.2.4). |
| Poisons Standard, October 2026 | Schedule 4 and Appendix D clause 5 item 7, CAS No. 863288-34-0 (instrument F2026L01327, read 1 October 2026 UTC). |
| WADA 2026 list | Named under S2.2.4, prohibited at all times (WADA 2026 List). |
| Approval as a medicine, 2026 | Not approved by FDA or EMA, according to a 2026 narrative review (Dominikowski et al., 2026). An openFDA search of Drugs@FDA applications on 14 October 2026 found no CJC-1295 application (search). |
What is CJC-1295 with DAC?
CJC-1295 with DAC is a lab-made peptide, a short chain of amino acids. It is built from the first 29 amino acids of human growth hormone-releasing factor, with four swaps and one added lysine. The lysine carries a reactive maleimide group. That group bonds to cysteine 34 of albumin, a blood protein. In rats the peptide stayed in plasma beyond 72 hours. That is an animal result, not a human measurement (Jetté et al., 2005). DAC stands for drug affinity complex. In two placebo-controlled trials of healthy adults aged 21 to 61, the estimated half-life was 5.8 to 8.1 days. The abstract gives no head count (Teichman et al., 2006).
Albumin is a protein your liver already makes in large amounts. It carries other molecules around your blood. The hook lets the peptide travel attached to it. The Jetté paper presents that attachment as a way to make a peptide last longer in the blood.
The DAC and no DAC comparison guide sets the two molecules side by side. It gives their registry numbers and the published half-life record.
What is no DAC in CJC-1295?
No DAC means the form of CJC-1295 without the drug affinity complex, the albumin-binding hook. It keeps the 29-amino-acid backbone and drops the added lysine and hook (Jetté et al., 2005). A 2026 narrative review calls this form Mod GRF 1-29. It says the form has no peer-reviewed human studies. It puts the form in the lowest of four evidence tiers (Dominikowski et al., 2026). The human results of Teichman et al. (2006) and Ionescu and Frohman (2006) are about the DAC form. They do not show results for the without-DAC form.
A name on a label is a claim to check. Two molecules can share the CJC-1295 name but differ in length, published evidence and registry record. The comparison guide explains why a paper about one form cannot simply be used for the other.
Is CJC-1295 a steroid?
No, CJC-1295 is not a steroid. It is a peptide, a chain of amino acids. Anabolic steroids are a separate drug family. The World Anti-Doping Agency (WADA) files them in different classes. Anabolic androgenic steroids sit in S1, anabolic agents. CJC-1295 sits in S2.2.4, growth hormone releasing factors, within the peptide hormones class (WADA Prohibited List 2026, in effect from 1 January 2026). Both classes are prohibited at all times in sport. That is a sport rule. It does not mean the two work alike.
Online talk often lumps every performance-related product together. A 2026 narrative review warns that people who use these peptides often use other products too, including anabolic-androgenic steroids. So a change blamed on one peptide may come from several exposures (Dominikowski et al., 2026).
Is CJC-1295 a growth hormone?
No, CJC-1295 is not a growth hormone. It is a lab-made copy of the signal that tells the pituitary gland to make and release its own growth hormone (Jetté et al., 2005; Teichman et al., 2006). WADA lists growth hormone and its analogues in class S2.2.3. It lists growth hormone releasing factors such as CJC-1295 in class S2.2.4 (WADA Prohibited List 2026). Growth hormone pulses were kept in healthy men aged 20 to 40, sampled overnight one week after one exposure. The abstract gives no head count. That is a hormone-level result from one study (Ionescu and Frohman, 2006).
The difference matters for how the body responds. Your pituitary also listens to feedback signals. So a releasing factor works inside the body's own control loops. A 2026 narrative review notes that GHRH analogues act upstream of growth hormone release. Their effects are still shaped by control loops such as somatostatin tone and IGF-1 feedback. Long-acting versions can give more lasting stimulation (Dominikowski et al., 2026).
Does CJC-1295 affect or suppress testosterone?
No human study found for this page reports testosterone as a CJC-1295 outcome. On 14 October 2026, a Europe PMC search for CJC-1295 with testosterone returned 13 records. By title, none is a CJC-1295 trial. WADA's 2026 list puts CJC-1295 under growth hormone releasing factors, S2.2.4. It does not put it under S2.2.1, testosterone-stimulating peptides. A 2026 narrative review has a table of hormone signals across growth hormone-axis peptides. The table has no testosterone row (Dominikowski et al., 2026). The question is unstudied in the records searched. So neither an effect nor its absence can be claimed.
The records that mention both names are mostly reviews, doping-analysis papers and surveys of people using several products. Surveys like that cannot separate one peptide from the others a person uses. That is the same mixing-up problem the 2026 review describes.
Did CJC-1295 studies measure testosterone?
The main CJC-1295 paper lists no testosterone result in its abstract. An abstract is the short report at the start. Teichman and colleagues tracked growth hormone and IGF-I in healthy adults. IGF-I is a separate growth signal. A change in those blood tests cannot show a change in testosterone. It leaves claims of a rise or fall unconfirmed.
The Endocrine Society guide covers men with signs of low testosterone. Blood tests must also show clearly low levels. Its scope differs from the CJC-1295 study (Bhasin and colleagues, 2018). Read the guide for that group.
The FDA page is about testosterone medicines. It does not test them against CJC-1295. These sources cannot tell you which has less risk. That needs a fair test of the same outcome in similar groups.

Can CJC-1295 cause insulin resistance?
None of the CJC-1295 human papers read for this page reports insulin resistance as a result. Blood sugar is still a known question for the whole class. The US label for tesamorelin carries a warning of glucose intolerance based on its clinical trials. Tesamorelin is an approved GHRH analogue for HIV-infected adults with lipodystrophy. The label passage read gives no head count for its HbA1c figures, so this page does not repeat them. The warning belongs to that medicine, not to CJC-1295 (Egrifta WR label, DailyMed updated 29 July 2026). A 2026 narrative review calls the blood sugar signal variable. It calls the link to too much growth hormone theoretical (Dominikowski et al., 2026).
The abstracts of the two main CJC-1295 human papers report hormone results and safety conclusions. Neither reports glucose or insulin results (Teichman et al., 2006; Ionescu and Frohman, 2006). Growth hormone is known to work against insulin in the body. That is why the question is asked at all. No study found measured whether this holds for CJC-1295 in people over months.
Have studies tested strength with CJC-1295 and ipamorelin?
No, studies have not tested strength with CJC-1295 and ipamorelin. No published trial found for this page measures strength after CJC-1295, ipamorelin or the pair. The two cited CJC-1295 papers report hormone measures in healthy adults. Neither abstract gives a head count or a strength outcome (Teichman et al., 2006; Ionescu and Frohman, 2006). The ipamorelin human data are a study of how the body handles the drug, in eight healthy men at each of five levels (Gobburu et al., 1999). The other is a small phase 2 proof-of-concept trial of 117 enrolled patients after bowel surgery, with 114 analysed. It found no clear difference from placebo on its key endpoint (Beck et al., 2014). A 2026 narrative review rates controlled evidence for performance outcomes in healthy people as limited (Dominikowski et al., 2026).
The muscle and body-composition record is on the page on what studies found CJC-1295 does. It includes the mouse study and the tesamorelin trial.
Evidence limits
What are the downsides and unknowns of CJC-1295?
The recorded downsides of CJC-1295 are mostly gaps. According to a 2026 narrative review, it is not an approved medicine, and no long-term human safety data exist (Dominikowski et al., 2026). The review reports finding no peer-reviewed human studies of CJC-1295 without DAC. That is the review's finding. It is not proof that no such study exists. The only registered phase 2 trial found was ended early with no results posted (ClinicalTrials.gov NCT00267527, checked 14 October 2026). The FDA lists serious adverse events linked to CJC-1295, including faster heart rate and a body-wide blood vessel widening reaction. It says clinical data are limited and names no source (FDA page, current as of 22 April 2026). CJC-1295 is also named in the Australian Poisons Standard and prohibited in sport.
Each gap has its own page. The CJC-1295 side effects page sets out the adverse events recorded in studies and by regulators. The TGA's advisory of 13 April 2026 adds that unapproved peptide products have not been assessed for safety, quality or effectiveness. What they contain and what side effects they cause are among the unknowns.
How well studied is CJC-1295 compared with other growth hormone-releasing peptides?
A 2026 narrative review sorts growth hormone-axis peptides into four evidence tiers. Tesamorelin sits in tier A, backed by randomised trials within an approved use. The review puts CJC-1295 with DAC in tier B and describes phase I studies in healthy adults without controlled efficacy data. That is the review's own assessment. It puts CJC-1295 without DAC in tier D and reports finding no peer-reviewed human studies. That does not show that no such study exists (Dominikowski et al., 2026). The tiers describe how much evidence one review found. They do not rate how good a peptide is.
Whether a peptide is a good one is a judgement, not a study measurement. What can be said is how much has been tested, in whom, and for how long. For CJC-1295 with DAC, that is short trials in healthy adults. For the without-DAC form, it is nothing in people in the sources checked.
What is the legal and sport status of CJC-1295 in Australia?
The October 2026 Poisons Standard instrument, F2026L01327, lists CJC-1295 with CAS No. 863288-34-0 in Schedule 4 and in Appendix D, clause 5, item 7. This is according to the Australian law guide, which read it on 1 October 2026 UTC. The Federal Register of Legislation shows the instrument in force on 14 October 2026. The entry names one CAS number and does not say which form it covers. WADA's 2026 list names CJC-1295 under S2.2.4. These entries are classifications. They do not decide anyone's legal position.
The TGA's advisory of 13 April 2026 names CJC-1295 as an example of an unapproved peptide product. It states that a research-use-only label does not make supply lawful. Sport Integrity Australia's peptides page, read 14 October 2026, lists CJC-1295 among common unapproved peptides prohibited in sport.
Is research-use CJC-1295 the peptide in these studies?
Not necessarily. Published results describe the sponsor's trial product, tested in enrolled healthy adults under trial conditions (Teichman et al., 2006). Research-use reference material is a lab compound with its own paperwork. A certificate describes one sample and one lot. Research material is not a medicine and not a substitute for one. It is not for human or animal use. A paper about the DAC form is background for naming. It is not evidence about a No DAC sample.
The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial, with the split unstated. A certificate of analysis describes one sample. It does not carry a study's results across. The CJC-1295 and ipamorelin research guide covers the compound families.
Comparison
These evidence tiers were assigned by a 2026 narrative review (Dominikowski et al.). Tesamorelin is an approved medicine for one condition. It is shown for contrast only.
| Compound | Evidence tier | Human evidence in the review | Approval status |
|---|---|---|---|
| Tesamorelin | A | Randomised controlled trials within an approved indication | Approved in the United States for excess abdominal fat in adults with HIV and lipodystrophy (Egrifta SV label, DailyMed updated 29 July 2026). |
| CJC-1295 with DAC | B | Dominikowski et al. (2026) describe phase I pharmacokinetic and pharmacodynamic studies in healthy adults and no controlled efficacy data for the DAC form. This is one narrative review's assessment. | Not approved by FDA or EMA, according to the review. No Drugs@FDA application found in an openFDA search on 14 October 2026 (search). |
| CJC-1295 without DAC | D | Dominikowski et al. (2026) report finding no peer-reviewed human studies of the without-DAC form and describe claims as extrapolation and user narratives. This is one narrative review's assessment. | Not approved by FDA or EMA, according to the review |
FAQ
Is CJC-1295 a steroid?
No, CJC-1295 is not a steroid. It is a peptide. WADA files it under S2.2.4, growth hormone releasing factors. Anabolic steroids sit in S1 (WADA Prohibited List 2026).
Is CJC-1295 a growth hormone?
No, CJC-1295 is not a growth hormone. It is a lab-made analogue of growth hormone-releasing hormone. Jetté et al. (2005) reported activity at the pituitary GHRH receptor in rat tests. That animal finding does not show a human response.
Does CJC mess with testosterone?
No human study found in a Europe PMC search on 14 October 2026 reports testosterone as a CJC-1295 outcome. The question is unstudied in the records searched.
What does DAC stand for?
DAC stands for drug affinity complex. In CJC-1295 the added lysine carries a reactive group. Bonding to albumin was seen in rats. This animal finding does not show the same result in humans (Jetté et al., 2005).
Is CJC a good peptide, according to studies?
That is a judgement, not a measurement. The evidence found is two short trials in healthy adults for the DAC form. The abstract gives no head count. For the without-DAC form, a 2026 narrative review found no peer-reviewed human studies (Dominikowski et al., 2026; Teichman et al., 2006).
Is CJC-1295 approved as a medicine?
No, CJC-1295 is not approved as a medicine. A 2026 narrative review states that neither CJC-1295 variant is approved by major regulators such as the FDA or EMA (Dominikowski et al., 2026). An openFDA search of Drugs@FDA applications on 14 October 2026 found no CJC-1295 application (search).
More in this hub
- CJC-1295 side effects: what studies and regulators have recorded
- What does CJC-1295 do? What published studies found
- Tesamorelin vs CJC-1295 vs ipamorelin: what do the studies show?
- Is CJC-1295 legal in Australia? TGA, FDA and WADA status
- CJC-1295 half-life and pharmacokinetics: what do the studies show?
Citations
7 sourcesJetté L, Léger R, Thibaudeau K, et al. Endocrinology. 2005;146(7):3052-3058.
doi:10.1210/en.2004-1286Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
doi:10.1210/jc.2005-1536Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
doi:10.1210/jc.2006-1702Dominikowski A, Rękoś Z, Olejarz M, et al. Frontiers in Endocrinology. 2026;17:1822475.
doi:10.3389/fendo.2026.1822475Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical Research. 1999;16(9):1412-1416.
doi:10.1023/a:1018955126402Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. International Journal of Colorectal Disease. 2014;29(12):1527-1534.
doi:10.1007/s00384-014-2030-8Bhasin S et al. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744.
doi:10.1210/jc.2018-00229
Continue
CJC-1295 (No DAC) & ipamorelin reference materialResearch use only: not for human or animal use.
Read the CJC-1295 and ipamorelin research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
